%0 Journal Article %A Manfred G Kitzbichler %A Athina R Aruldass %A Gareth J Barker %A Tobias C Wood %A Nicholas G Dowell %A Samuel A Hurley %A John McLean %A Marta Correia %A Charlotte Clarke %A Linda Pointon %A Jonathan Cavanagh %A Phil Cowen %A Carmine Pariante %A NIMA consortium %A Mara Cercignani %A Edward T Bullmore %A Neil A Harrison %T Peripheral inflammation is associated with micro-structural and functional connectivity changes in depression-related brain networks %D 2020 %R 10.1101/2020.09.09.20191262 %J medRxiv %P 2020.09.09.20191262 %X Peripheral inflammation can cause depressive symptoms – but how? Here, we measured brain MRI functional connectivity and micro-structural parameters, including proton density (PD, a measure of tissue water), at 360 cortical and 16 subcortical brain regions in 46 healthy controls and 83 depressed cases. Blood C-reactive protein (CRP) was positively correlated with PD in key precuneus/posterior cingulate cortex (pC/pCC) and medial prefrontal cortex (mPFC) components of the default mode network (DMN). CRP concentration was associated with increased connectivity within the DMN (nodes pC/pCC, mPFC and hippocampus), but decreased connectivity between DMN and non-DMN nodes. Depressed cases had reduced weighted degree, a metric of hubness, in anatomically co-located DMN regions. Our interpretation is that low-grade peripheral inflammation is associated with increased water (oedema) within a few highly connected but metabolically vulnerable medial cortical nodes, and this “rock in the pond” serves to perturb the functional connectivity of large-scale cortico-subcortical systems associated with depression.Competing Interest StatementETB is a member of the scientific advisory board of Sosei Heptares. The authors declare no competing interests. Funding StatementThis study was funded by an award from the Wellcome Trust (grant number: 104025/Z/14/Z) for the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA) consortium, which was also funded by Janssen, GlaxoSmithKline, Lundbeck and Pfizer. Additional support was provided by the NIHR Cambridge Biomedical Research Centre. ETB is an NIHR Senior Investigator.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All procedures were approved by an independent Research Ethics Committee (National Research Ethics Service East of England, Cambridge Central, UK) and the study was conducted according to the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and processing scripts will be made available. %U https://www.medrxiv.org/content/medrxiv/early/2020/09/18/2020.09.09.20191262.full.pdf